Clinical Trial Update: Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3 study comparing NVA237 to tiotropium in patients with chronic obstructive pulmonary disease to evaluate efficacy, safety, and tolerability; results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237
• tiotropium (tiotropium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-04-23